OBJECTIVE: To evaluate the survival impact of residual disease at the time of primary surgery for patients with Stage III and IV endometrial carcinoma; to assess morbidity associated with surgical cytoreduction. METHOD: All patients with endometrial carcinoma who underwent primary surgical therapy at the University of Miami between January 1, 1990 and June 1, 2002 were identified. Patients meeting FIGO criteria for Stage III or IV disease were selected. Papillary serous and clear cell histology was excluded. RESULTS: Eighty-five patients were identified: 66 Stage III and 19 Stage IV. Only Stage IIIC and Stage IV were included in survival analysis: 72% (33 Stage IIIC, 9 Stage IV) had optimal cytoreduction and 28% (6 Stage IIIC, 10 Stage IV) had suboptimal cytoreduction. The median survival for Stage IIIC and IV disease was 6.7 months for patients with suboptimal cytoreduction and 17.8 months for patients with optimal cytoreduction (P = 0.001). The proportion of patients with major postoperative complications (37.50% vs. 7.25%, P = 0.005), unplanned postoperative SICU admissions (31.25% vs. 7.25%, P = 0.018), and length of hospital stay exceeding 15 days (31.25% vs. 4.35%, P = 0.005) was greater in patients with suboptimal cytoreductive surgery. CONCLUSIONS: Overall survival is lower and morbidity is higher in patients with advanced endometrial carcinoma having suboptimal cytoreduction at the time of primary surgery. Patients with suspected advanced stage endometrial carcinoma should be counseled on the potential benefits of optimal cytoreductive surgery. Alternative treatment options should be considered in those patients with surgically unresectable disease.
OBJECTIVE: To evaluate the survival impact of residual disease at the time of primary surgery for patients with Stage III and IV endometrial carcinoma; to assess morbidity associated with surgical cytoreduction. METHOD: All patients with endometrial carcinoma who underwent primary surgical therapy at the University of Miami between January 1, 1990 and June 1, 2002 were identified. Patients meeting FIGO criteria for Stage III or IV disease were selected. Papillary serous and clear cell histology was excluded. RESULTS: Eighty-five patients were identified: 66 Stage III and 19 Stage IV. Only Stage IIIC and Stage IV were included in survival analysis: 72% (33 Stage IIIC, 9 Stage IV) had optimal cytoreduction and 28% (6 Stage IIIC, 10 Stage IV) had suboptimal cytoreduction. The median survival for Stage IIIC and IV disease was 6.7 months for patients with suboptimal cytoreduction and 17.8 months for patients with optimal cytoreduction (P = 0.001). The proportion of patients with major postoperative complications (37.50% vs. 7.25%, P = 0.005), unplanned postoperative SICU admissions (31.25% vs. 7.25%, P = 0.018), and length of hospital stay exceeding 15 days (31.25% vs. 4.35%, P = 0.005) was greater in patients with suboptimal cytoreductive surgery. CONCLUSIONS: Overall survival is lower and morbidity is higher in patients with advanced endometrial carcinoma having suboptimal cytoreduction at the time of primary surgery. Patients with suspected advanced stage endometrial carcinoma should be counseled on the potential benefits of optimal cytoreductive surgery. Alternative treatment options should be considered in those patients with surgically unresectable disease.
Authors: Cherie P Parungo; David I Soybel; Yolonda L Colson; Sang-Wook Kim; Shunsuke Ohnishi; Alec M DeGrand; Rita G Laurence; Edward G Soltesz; Fredrick Y Chen; Lawrence H Cohn; Moungi G Bawendi; John V Frangioni Journal: Ann Surg Oncol Date: 2007-02 Impact factor: 5.344
Authors: Andrea Papadia; Maria Luisa Gasparri; Alessandro Buda; Michael D Mueller Journal: J Cancer Res Clin Oncol Date: 2017-08-21 Impact factor: 4.553
Authors: Joan L Walker; Marion R Piedmonte; Nick M Spirtos; Scott M Eisenkop; John B Schlaerth; Robert S Mannel; Gregory Spiegel; Richard Barakat; Michael L Pearl; Sudarshan K Sharma Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Benjamin B Albright; Karen A Monuszko; Samantha J Kaplan; Brittany A Davidson; Haley A Moss; Allan B Huang; Alexander Melamed; Jason D Wright; Laura J Havrilesky; Rebecca A Previs Journal: Am J Obstet Gynecol Date: 2021-05-04 Impact factor: 10.693
Authors: I Vandenput; B Van Calster; A Capoen; K Leunen; P Berteloot; P Neven; Ph Moerman; I Vergote; F Amant Journal: Br J Cancer Date: 2009-06-30 Impact factor: 7.640
Authors: Claire J Tobias; Ling Chen; Alexander Melamed; Caryn St Clair; Fady Khoury-Collado; Ana I Tergas; June Y Hou; Chin Hur; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright Journal: JAMA Netw Open Date: 2020-12-01
Authors: Jason D Wright; Yongmei Huang; Alexander Melamed; Benjamin B Albright; Grace C Hillyer; Rebecca Previs; M S Dawn L Hershman Journal: Gynecol Oncol Date: 2021-06-20 Impact factor: 5.304